Headquarters: Osaka, Japan
Industry sector: Pharmaceuticals
Takeda has become the largest pharmaceutical company in Asia, thanks in large part to its astute approach to IP management. In 2009 it created the post of chief scientific officer with a mandate to oversee the global R&D and IP functions, in order to ensure that both work seamlessly together and to facilitate dialogue between the boardroom and the labs. A string of strategic acquisitions have allowed it to survive the patent cliff and consolidate its position as a global player. In 2008 it bought Massachusetts-based Millennium and Amgen’s Japanese unit to gain access to technology and patents in the biotechnology and oncology spaces, while the $13.7 billion acquisition of Nycomed in 2011 – its biggest overseas purchase to date – allowed it to expand into Europe and other new markets. The group’s global IP footprint now includes 120 professionals, half of whom are based outside of Japan. Takeda has also rolled out a successful licensing programme: its royalty income in 2012 totalled some $455 million.